Psychopharmacologia

, Volume 43, Issue 1, pp 53–61 | Cite as

Neuropharmacological studies on D145 (1,3-dimethyl-5-aminoadamantan)

  • B. Costall
  • R. J. Naylor
Animal Studies

Abstract

The effects of D145 (1,3-dimethyl-5-aminoadamantan) and amantadine on dopaminergic mechanisms in the rat were investigated by use of pharmacological agents known to disrupt dopamine function, by placing electrolytic lesions in the dopamine-containing areas of the extrapyramidal and mesolimbic systems and by the direct application to dopamine sensitive areas. Stereotypy and circling behaviour were used as behavioural indices of dopaminergic stimulation and apomorphine and d-amphetamine were used as standard dopaminergic agonists. In addition, the possible importance of 5-hydroxytryptamine to the dopamine effects was investigated using electrolytic lesions of the midbrain raphé nuclei.

Both D145 and amantadine caused a stereotyped behaviour characterised by periodic sniffing, repetitive limb movements and biting, but the effect of amantadine was far more periodic. In addition D145, but not amantadine, caused marked hyperactivity. These behavioural effects were resistant to pretreatment with α-methylparatyrosine but not to combined α-methylparatyrosine/reserpine or low doses of haloperidol. Also, the prior administration of D145 or amantadine inhibited the development of the biting components of apomorphine and d-amphetamine stereotypy. Both D145 and amantadine caused circling behaviour in animals with asymmetric lesions of the medial raphé nucleus or unilateral lesions of the substantia nigra but the action of D145 was more intense. Bilateral electrolytic lesions placed in the extrapyramidal (caudate-putamen, globus pallidus, substantia nigra), mesolimbic (nucleus accumbens septi, tuberculum olfactorium, nucleus interstitialis stria terminalis, nucleus amygdaloideus centralis) nuclei or the neuronal pathways supplying them showed D145 and amantadine to act in both areas although their action on the extrapyramidal system was most marked. However, of particular note was the significantly greater involvement of the substantia nigra with the D145 effect, and the greater involvement of the D145 effect with mesolimbic function. Lesions placed in the medial and/or dorsal raphé nucleus indicated some involvement of 5-hydroxytryptamine with the actions of both D145 and amantadine. The bilateral intrastriatal application of D145 or amantadine in nialamide pretreated animals failed to induce stereotyped or hyperactive behaviour although contralateral asymmetries, which were abolished by lesions of the substantia nigra, were recorded following the unilateral intrastriatal application of D145 or amantadine in haloperidol pretreated animals.

Key words

Adamantane Derivatives Parkinsonism Dopamine Stereotyped Behaviour Circling Behaviour Extrapyramidal System Mesolimbic System Raphé Nuclei 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Andén, N.-E.: Effects of amphetamine and some other drugs on central catecholamine mechanisms. In: International Symposium on amphetamine and related compounds. E. Costa and S. Garattini, eds., pp. 447–462. New York: Raven Press 1970Google Scholar
  2. Costall, B., Naylor, R. J.: The role of telencephalic dopaminergic systems in the mediation of apomorphine stereotyped behaviour. Europ. J. Pharmacol. 24, 8–24 (1973a)Google Scholar
  3. Costall, B., Naylor, R. J.: Neuroleptic and non-neuroleptic catalepsy. Arzneimittel-Forsch. 23, 674–683 (1973b)Google Scholar
  4. Costall, B., Naylor, R. J.: The importance of the ascending dopaminergic systems to the extrapyramidal and mesolimbic brain areas for the cataleptic action of the neuroleptic and cholinergic agents. Neuropharmacology 13, 353–364 (1974a)Google Scholar
  5. Costall, B., Naylor, R. J.: Stereotyped and circling behaviour induced by dopaminergic agonists after lesions of the midbrain raphé nuclei. Europ. J. Pharmacol. 29, 206–222 (1974b)Google Scholar
  6. Costall, B., Naylor, R. J.: Specific asymmetric behaviour induced by the direct chemical stimulation of neostriatal dopaminergic mechanisms. Naunyn-Schmiedeberg's Arch. Pharmacol. 285, 83–91 (1974c)Google Scholar
  7. Costall, B., Naylor, R. J.: A comparison of the action of dopaminergic agonists on motor function. In: Symposium on drugs acting on dopamine receptors. Adv. Neurol. Vol. 9. D. B. Calne, T. N. Chase, and A. Barbeau, eds., pp. 285–297. New York: Raven Press 1975Google Scholar
  8. Costall, B., Naylor, R. J., Pinder, R. M.: Design of agents for stimulation of neostriatal dopaminergic mechanisms. J. Pharm. Pharmacol. 26, 753–762 (1974)Google Scholar
  9. De Groot, J.: The rat brain in stereotaxic coordinates. Verh. K. Ned. Akad. Wet. 52, 14–39 (1959)Google Scholar
  10. Gilligan, B.: Effectiveness of symmetrel in different forms of Parkinsonism. In: Parkinson's disease. A new approach to treatment. G. F. B. Birdwood, S. S. B. Gilder, and C. A. S. Wink, eds., pp. 5–12. London: Academic Press 1971Google Scholar
  11. Hackman, R., PentikÄinen, P., Neuroven, R. J., Vapaatalo, H.: Inhibition of apomorphine gnawing compulsion by amantadine. Experientia (Basel) 29, 1524–1525 (1973)Google Scholar
  12. König, J. F. R., Klippel, R. A.: The rat brain. A stereotaxic atlas of the forebrain and lower parts of the brain stem. Baltimore: Williams and Wilkins 1963Google Scholar
  13. Kostowski, W., Giacalone, E., Garattini, S., Valzelli, L.: Studies on behavioural and biochemical changes in rats after lesion of midbrain raphé. Europ. J. Pharmacol. 4, 371–376 (1968)Google Scholar
  14. Kuhar, M. J., Roth, R. H., Aghajanian, G. K.: Selective reduction of tryptophan hydroxylose activity in rat forebrain after midbrain raphé lesions. Brain Res. 35, 167–176 (1971)Google Scholar
  15. Marsden, C. A., Guldberg, H. C.: The role of monoamines in rotation induced or potentiated by amphetamine after nigral, raphé and mesencephalic reticular lesions in the rat brain. Neuropharmacology 12, 195–211 (1972)Google Scholar
  16. Parkes, J. D., Baxter, R. C., Galbraith, A., Marsden, C. D., Rees, J. E.: Amantadine treatment of Parkinson's disease. In: Progress in the treatment of Parkinsonism. D. B. Calne, ed., Adv. Neurol. Vol. 3, pp. 105–114. New York: Raven Press 1973Google Scholar
  17. Sacks, O. W., Schwartz, W. F., Messeloff, C. R.: Interactions of l-dopa and amantadine in Parkinsonism. Clin. Pharmacol. Ther. 12, 301–304 (1971)Google Scholar
  18. Ungerstedt, U.: Stereotaxic mapping of the monoamine pathways in the rat brain. Acta physiol. scand., Suppl. 367, 1–48 (1971)Google Scholar
  19. Ungerstedt, U., Avemo, A., Avemo, E., Ljungberg, T., Ranje, C.: Animal models of Parkinsonism. In: Progress in the treatment of Parkinsonism. D. B. Calne, ed., Adv. Neurol. Vol.3, pp. 257–271. New York: Raven Press 1973Google Scholar

Copyright information

© Springer-Verlag 1975

Authors and Affiliations

  • B. Costall
    • 1
  • R. J. Naylor
    • 1
  1. 1.Postgraduate School of Studies in PharmacologyUniversity of BradfordBradfordEngland

Personalised recommendations